1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Direct Link:
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report
Article first published online: 1 AUG 2003
DOI: 10.1002/art.11137
Copyright © 2003 by the American College of Rheumatology
Additional Information
How to Cite
Gómez-Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M. and Montero, M. D. (2003), Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis & Rheumatism, 48: 2122–2127. doi: 10.1002/art.11137
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 1 AUG 2003
- Manuscript Accepted: 22 APR 2003
- Manuscript Received: 17 JAN 2003
Funded by
- Agencia Española del Medicamento (Ministerio de Sanidad y Consumo)
- Spanish Society of Rheumatology
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases, Inflammatory Bowel Diseases, 2011, 17, 1
- 2, , , , , , , Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis, The Journal of Gene Medicine, 2010, 12, 1Direct Link:
- 3, , , , , , Creation of TNFR1-selective Antagonist and Its Therapeutic Effects, YAKUGAKU ZASSHI, 2010, 130, 1, 63
- 4, , , , , , , , , Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis, Rheumatology International, 2010,
- 5, , Do RANKL inhibitors (denosumab) affect inflammation and immunity?, Osteoporosis International, 2010,
- 6, , , , , , , ELISPOT-IFN-γ assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-α treatment, Clinical Rheumatology, 2010, 29, 10, 1135
- 7, , , , , , , , , , , , , , , Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass, Diabetologia, 2010, 53, 4, 614
- 8, , , Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider Arthritis, Zeitschrift für Rheumatologie, 2010, 69, 10, 879
- 9, , , , , , , , Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review, Clinical Rheumatology, 2010, 29, 6, 629
- 10, , , , , , , , , Preventing tuberculosis in children receiving anti-tnf treatment, Clinical Rheumatology, 2010, 29, 4, 389
- 11, , , Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions, Modern Rheumatology, 2010, 20, 3, 222
- 12, , , , , , Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0, Rheumatology, 2010, 50, 1, 85
- 13, , , , , , , , Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience, Journal of Gastroenterology and Hepatology, 2010, 25, 11Direct Link:
- 14, , , , , , Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series, Clinical Rheumatology, 2010, 29, 6, 677
- 15, , , , , , , , , Targeting interleukin-21 in rheumatoid arthritis, Molecular Biology Reports, 2010,
- 16, , , Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis, International Journal of Rheumatic Diseases, 2010, 13, 1Direct Link:
- 17, , , , , A case of lung tuberculosis in a patient with rheumatoid arthritis treated with infliximab after antituberculosis chemoprophylaxis with isoniazid, Modern Rheumatology, 2009, 19, 3, 323
- 18, , , , , A Case of Tuberculous Arthritis Following the Use of Etanercept, The Korean Journal of Internal Medicine, 2009, 24, 4, 397
- 19, , , , , , Abdominal Pain in a Patient With Ankylosing Spondylitis Under Treatment With Infliximab, JCR: Journal of Clinical Rheumatology, 2009, 15, 5, 244
- 20, , , , , , , , Anti-TNF immunotherapy reduces CD8+ T cell–mediated antimicrobial activity against Mycobacterium tuberculosis in humans, Journal of Clinical Investigation, 2009, 119, 5, 1167
- 21, , , Biomarkers for tuberculosis disease status and diagnosis, Current Opinion in Pulmonary Medicine, 2009, 15, 3, 181
- 22, , , , , , , , , , , , , British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009, British Journal of Dermatology, 2009, 161, 5Direct Link:
- 23, , , , , , Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population, Clinical and Experimental Medicine, 2009, 10, 3, 173
- 24, Development of Novel DDS Technologies for Optimized Protein Therapy by Creating Functional Mutant Proteins with Antagonistic Activity, YAKUGAKU ZASSHI, 2009, 129, 8, 933
- 25, , , , , , , Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval, Drug Safety, 2009, 32, 12, 1175
- 26, , , , , , , , Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis, Rheumatology International, 2009, 30, 11, 1459
- 27, , , , , Initiation of rheumatoid arthritis treatments and the risk of serious infections, Rheumatology, 2009, 49, 1, 82
- 28, , , , , , Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept, Clinical Rheumatology, 2009, 29, 1, 99
- 29, , , Modulation of T-Cell Co-Stimulation in Rheumatoid Arthritis, Clinical Drug Investigation, 2009, 29, 3, 185
- 30, , Pulmonary Complications of Antirheumatic Therapies, Clinical Pulmonary Medicine, 2009, 16, 6, 315
- 31, , , , , , , , , , , , , , , Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry, Arthritis & Rheumatism, 2009, 60, 7Direct Link:
- 32, , The clinical utility of inhibiting CD28-mediated costimulation, Immunological Reviews, 2009, 229, 1Direct Link:
- 33, , , , , , , , , , , Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse, Gene Therapy, 2009, 16, 8, 982
- 34, , , , , Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab, Rheumatology International, 2009, 29, 11, 1381
- 35, , , , , Using ‘number needed to treat’ to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-α inhibitors for patients with severe psoriasis, British Journal of Dermatology, 2009, 161, 3Direct Link:
- 36, , , , Association of infections and tuberculosis with antitumor necrosis factor alpha therapy, Current Opinion in Rheumatology, 2008, 20, 3, 320
- 37, , , Derivation and Validation of a Clinical Prediction Score for Isolation of Inpatients With Suspected Pulmonary Tuberculosis • , Infection Control and Hospital Epidemiology, 2008, 29, 10, 927
- 38, , Determinants of natural immunity against tuberculosis in an endemic setting: factors operating at the level of macrophage–Mycobacterium tuberculosis interaction, Clinical & Experimental Immunology, 2008, 151, 3Direct Link:
- 39, , , , , Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy, Arthritis Care & Research, 2008, 59, 6Direct Link:
- 40, , , , , , , , , , , Etanercept provides a more physiological approach in the treatment of psoriasis, Dermatologic Therapy, 2008, 21,Direct Link:
- 41, , , , , , , Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab, Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 3Direct Link:
- 42, , , , , , , Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha, Clinical Rheumatology, 2008, 28, 4, 421
- 43, , , , , , Lack of Association between Cytokine Gene Polymorphisms and Silicosis and Pulmonary Tuberculosis in Chinese Iron Miners, Journal of Occupational Health, 2008, 50, 6, 445
- 44, , Leukocytapheresis for the treatment of IBD, Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5, 9, 509
- 45, , , Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues, Expert Opinion on Drug Safety, 2008, 7, 5, 617
- 46, , , , , , , , , , Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab, Arthritis & Rheumatism, 2008, 58, 5Direct Link:
- 47, Mycobacterial Disease Attributable to Tumor Necrosis Factor–α Blockers, Clinical Infectious Diseases, 2008, 47, 12, 1603
- 48, , , , Mycobacterial disease in patients with rheumatic disease, Nature Clinical Practice Rheumatology, 2008, 4, 12, 649
- 49, , Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2008, 27, 1Direct Link:
- 50, , , , , , , , Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy, Journal of Korean Medical Science, 2008, 23, 5, 852
- 51, , , , Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis, Expert Opinion on Investigational Drugs, 2008, 17, 5, 641
- 52, , Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies, Current Opinion in Rheumatology, 2008, 20, 4, 443
- 53, , , Tumor Necrosis Factor Blockers Influence Macrophage Responses toMycobacterium tuberculosis, The Journal of Infectious Diseases, 2008, 198, 12, 1842
- 54, , , , , , Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice, Arthritis & Rheumatism, 2007, 56, 8Direct Link:
- 55, , , , , , Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis, Gene Therapy, 2007, 14, 23, 1632
- 56
- 57, , , Biological therapies: new treatment options for ANCA-associated vasculitis?, Expert Opinion on Biological Therapy, 2007, 7, 4, 521
- 58, , CD3-specific antibodies: a portal to the treatment of autoimmunity, Nature Reviews Immunology, 2007, 7, 8, 622
- 59
- 60, , , , , , , , , , , , Do mitochondrial DNA haplogroups play a role in susceptibility to tuberculosis?, Respirology, 2007, 12, 6Direct Link:
- 61, , , , , , , , , , Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database, Internal Medicine Journal, 2007, 37, 9Direct Link:
- 62, , Guidelines for Prevention of Tuberculosis in Patients with Rheumatoid Arthritis Treated with TNF-alpha Blockers, The Journal of the Korean Rheumatism Association, 2007, 14, 2, 105
- 63, , , , , , , , , , , Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis, The Journal of Gene Medicine, 2007, 9, 7Direct Link:
- 64
- 65, , , , , , , , , , , Interferon γ assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration, Rheumatology International, 2007, 27, 12, 1143
- 66, , , , Listeria infections associated with infliximab: case reports, Clinical Rheumatology, 2007, 26, 12, 2173
- 67, , , , Ocular manifestations of Wegener?s granulomatosis, Expert Review of Ophthalmology, 2007, 2, 1, 91
- 68, , Opportunistic infections associated with TNF-α treatment, Future Rheumatology, 2007, 2, 6, 567
- 69
- 70, , , Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection, Arthritis Care & Research, 2007, 57, 5Direct Link:
- 71, , , , The Immuno-endocrine Component in the Pathogenesis of Tuberculosis, Scandinavian Journal of Immunology, 2007, 66, 2-3Direct Link:
- 72, , The use of TNF-α blocking agents in rheumatoid arthritis: an update, Expert Opinion on Pharmacotherapy, 2007, 8, 13, 2089
- 73, , , , TLR2 but not TLR4 Signalling is Critically Involved in the Inhibition of IFN-γ-induced Killing of Mycobacteria by Murine Macrophages, Scandinavian Journal of Immunology, 2007, 65, 2Direct Link:
- 74, , , , , Treatment of psoriasis with adalimumab, Clinical and Experimental Dermatology, 2007, 32, 1Direct Link:
- 75
- 76
- 77, Tumor Necrosis Factor Blockade: Mechanism of Action, Journal of Investigative Dermatology Symposium Proceedings, 2007, 12, 1, 1
- 78, , Tumor necrosis factor inhibitors for the treatment of asthma, Current Allergy and Asthma Reports, 2007, 7, 2, 151
- 79, , , , , , , A tumor necrosis factor-α antagonist inhibits inflammatory bone resorption induced by Porphyromonas gingivalis infection in mice, Journal of Periodontal Research, 2006, 41, 2Direct Link:
- 80, Adverse side-effects to biological agents, Allergy, 2006, 61, 8Direct Link:
- 81, , Anti-TNF-α agents in the treatment of psoriatic arthritis, Expert Opinion on Biological Therapy, 2006, 6, 2, 99
- 82, , , , Anti-Tumour Necrosis Factor-?? Therapy for Rheumatoid and Other Inflammatory Arthropathies, Drugs & Aging, 2006, 23, 11, 855
- You have free access to this content83, , , Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients, APLAR Journal of Rheumatology, 2006, 9, 2Direct Link:
- 84, , Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis, Nature Clinical Practice Rheumatology, 2006, 2, 4, 211
- 85, , , , Glucocorticoid use, other associated factors, and the risk of tuberculosis, Arthritis Care & Research, 2006, 55, 1Direct Link:
- 86, , , Impact of TNF inhibitors on rheumatoid arthritis, Inflammation and Regeneration, 2006, 26, 3, 148
- 87
- 88, , , Infliximab for rheumatoid arthritis, Expert Review of Clinical Immunology, 2006, 2, 2, 193
- 89
- 90, , , , Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis, Current Opinion in Rheumatology, 2006, 18, 1, 88
- 91, , Novel therapies for rheumatoid arthritis, Expert Opinion on Investigational Drugs, 2006, 15, 11, 1427
- You have free access to this content92, , , , Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents, APLAR Journal of Rheumatology, 2006, 9, 2Direct Link:
- 93, , , , , , , Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor α neutralizing antibody, Modern Rheumatology, 2006, 16, 1, 58
- 94, Pulmonary Infections in Patients with Rheumatoid Arthritis Who have Received Anti-TNF Therapy, Internal Medicine, 2006, 45, 17, 991
- 95, Quantifying risks: The case between glucocorticoids and tuberculosis, Arthritis Care & Research, 2006, 55, 1Direct Link:
- 96, , Recent advances in the etiology and treatment of inflammatory bowel disease, Expert Review of Clinical Immunology, 2006, 2, 2, 245
- 97, , , Risiko von Infektionen unter einer Behandlung mit Tumornekrosefaktor-α-Inhibitoren, Zeitschrift für Rheumatologie, 2006, 65, 1, 24
- You have free access to this content98, , , , , , Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-α antagonists, APLAR Journal of Rheumatology, 2006, 9, 2Direct Link:
- 99, , , , , , Role of anti-tumour necrosis factor-α therapeutic agents in the emergence of infections, Clinical Microbiology and Infection, 2006, 12, 12Direct Link:
- 100, The clinical application of etanercept in Chinese patients with rheumatic diseases, Modern Rheumatology, 2006, 16, 4, 206
- 101, , , The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease, Expert Opinion on Biological Therapy, 2006, 6, 5, 453
- 102, , , , Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors, Nature Medicine, 2005, 11, 10, 1066
- 103, , , , Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases, Allergology International, 2005, 54, 2, 191
- 104, , , , , , , , , , , , , , Detection of in vitro interferon-γ and serum tumour necrosis factor-α in multidrug-resistant tuberculosis patients, Clinical & Experimental Immunology, 2005, 141, 3Direct Link:
- 105, , , , , , , , Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis & Rheumatism, 2005, 52, 6Direct Link:
- 106, Etanercept in arthritis, International Journal of Clinical Practice, 2005, 59, 1Direct Link:
- 107
- 108, , , , , Etanerceptbehandlung bei rheumatoider Arthritis—monozentrische Langzeitbeobachtung über vier Jahre, Zeitschrift für Rheumatologie, 2005, 64, 4, 265
- 109, , Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management, Nephrology, 2005, 10, 4Direct Link:
- 110, , , , , , , , , Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis, Clinical & Experimental Immunology, 2005, 141, 2Direct Link:
- 111, , Infections Associated with Tumor Necrosis Factor-α Antagonists, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005, 25, 9Direct Link:
- 112, , , , , , , , , , , , Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis & Rheumatism, 2005, 52, 11Direct Link:
- 113, , , , , Infectious complications of tumor necrosis factor-α antagonists, International Journal of Dermatology, 2005, 44, 6Direct Link:
- 114, , Infliximab for the treatment of ankylosing spondylitis, Expert Opinion on Biological Therapy, 2005, 5, 8, 1095
- 115, , Infliximab for the treatment of early rheumatoid arthritis, Expert Opinion on Biological Therapy, 2005, 5, 3, 405
- 116, , , INTRODUCTION: Tumor Necrosis Factor Inhibition and Opportunistic Infections: Introduction, Clinical Infectious Diseases, 2005, 41, S3, S187
- 117, Rheumatoid Arthritis and Tuberculosis in the Tumor Necrosis Factor Inhibitors Era, JCR: Journal of Clinical Rheumatology, 2005, 11, 6, 344
- 118, , , , , , , , , , , , , , , Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden, Arthritis & Rheumatism, 2005, 52, 7Direct Link:
- 119, , , , , , , Successful Low Toxicity Hematopoietic Stem Cell Transplantation for High-Risk Adult Chronic Granulomatous Disease Patients, Transplantation, 2005, 79, 11, 1596
- 120, , Therapy of Progressive Rheumatoid Arthritis-Associated Corneal Ulceration With Infliximab, Cornea, 2005, 24, 6, 742
- 121, , , , , Tuberculosis associated with therapy against tumor necrosis factor α, Arthritis & Rheumatism, 2005, 52, 10Direct Link:
- 122, , , , Tuberculous Peritonitis, The American Journal of Gastroenterology, 2005, 100, 7, 1624
- 123, Tumor Necrosis Factor and Its Blockade in Granulomatous Infections: Differential Modes of Action of Infliximab and Etanercept?, Clinical Infectious Diseases, 2005, 41, S3, S199
- 124, , , Tumor necrosis factor antagonists and infections: The small print on the price tag, Arthritis Care & Research, 2005, 53, 5Direct Link:
- 125, , , Vaccination of brushtail possums, Trichosurus vulpecula, with Bacille Calmette-Guerin induces T lymphocytes that reduce Mycobacterium bovis replication in alveolar macrophages via a contact-dependent/nitric oxide-independent mechanism, Immunology and Cell Biology, 2005, 83, 1, 57
- 126, Adverse reactions to biological modifiers, Current Opinion in Allergy and Clinical Immunology, 2004, 4, 4, 277
- 127, , , , , , , , , , , , , , , , , , , , , , , Biological therapies in the systemic management of psoriasis: International Consensus Conference, British Journal of Dermatology, 2004, 151,Direct Link:
- 128, Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective, Therapy, 2004, 1, 2, 255
- 129, Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective, Therapy, 2004, 1, 2, 255
- 130
- 131, Editorial Commentary: Tumor Necrosis Factor Blockers and Reactivation of Latent Tuberculosis, Clinical Infectious Diseases, 2004, 39, 3, 300
- 132, , , , , , , , , , Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response, European Journal of Pediatrics, 2004, 164, 1, 13
- 133
- 134, , The use of TNF-α blocking agents in rheumatoid arthritis: an overview, Expert Opinion on Pharmacotherapy, 2004, 5, 3, 581
- 135, , Therapeutic advances in rheumatoid arthritis, APLAR Journal of Rheumatology, 2004, 7, 1Direct Link:
- 136, , , , , , Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor, Clinical Infectious Diseases, 2004, 39, 3, 295
- 137
- 138, , Adverse reactions to and safety of newer disease-modifying antirheumatic drugs for rheumatoid arthritis, Adverse Drug Reaction Bulletin, 2003, &NA;, 223, 855
- 139, Tuberculosis in the cytokine era: What rheumatologists need to know, Arthritis & Rheumatism, 2003, 48, 8Direct Link: